Literature DB >> 33572437

Combinations of Radiotherapy with Vaccination and Immune Checkpoint Inhibition Differently Affect Primary and Abscopal Tumor Growth and the Tumor Microenvironment.

Michael Rückert1, Lisa Deloch1, Benjamin Frey1, Eberhard Schlücker2, Rainer Fietkau1, Udo S Gaipl1.   

Abstract

Radiotherapy (RT) is known to have immune-modulatory properties. We hypothesized that RT and inactivated whole tumor cell vaccines generated with high hydrostatic pressure (HHP) synergize to retard the tumor growth which can be additionally improved with anti-PD-1 treatment. In abscopal tumor models, we injected mice with B16-F10 melanoma or TS/A mammary tumors. To evaluate the efficiency of RT in combination with HHP vaccines, we locally irradiated only one tumor with 2 × 8 Gy or 3 × 8 Gy. HHP vaccines further retarded the growth of locally irradiated (2 × 8 Gy) tumors. However, HHP vaccination combined with RT failed to induce abscopal anti-tumor immune responses, namely those to non-irradiated tumors, and even partly abrogated those which were induced with RT plus anti-PD-1. In the latter group, the abscopal effects were accompanied by an elevated infiltration of CD8+ T cells, monocytes/macrophages, and dendritic cells. 3 × 8 Gy failed to induce abscopal effects in association with increased expression of immunosuppressive checkpoint molecules compared to 2 × 8 Gy. We conclude that HHP vaccines induce anti-tumor effects, but only if the tumor microenvironment was previously modulated by hypofractionated RT with not too many fractions, but failed to improve RT plus anti-PD-induced abscopal responses that are characterized by distinct immune alterations.

Entities:  

Keywords:  abscopal effect; high hydrostatic pressure; immune checkpoint inhibition; radiotherapy; tumor microenvironment; tumor-infiltrating immune cells; vaccination

Year:  2021        PMID: 33572437      PMCID: PMC7916259          DOI: 10.3390/cancers13040714

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  67 in total

1.  In vitro study of immunosuppressive effect of apoptotic cells.

Authors:  Wen-Jin Zhang; Shu-Sen Zheng
Journal:  J Zhejiang Univ Sci B       Date:  2005-09       Impact factor: 3.066

2.  Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial.

Authors:  Encouse B Golden; Arpit Chhabra; Abraham Chachoua; Sylvia Adams; Martin Donach; Maria Fenton-Kerimian; Kent Friedman; Fabio Ponzo; James S Babb; Judith Goldberg; Sandra Demaria; Silvia C Formenti
Journal:  Lancet Oncol       Date:  2015-06-18       Impact factor: 41.316

3.  Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.

Authors:  Yared Hailemichael; Amber Woods; Tihui Fu; Qiuming He; Michael C Nielsen; Farah Hasan; Jason Roszik; Zhilan Xiao; Christina Vianden; Hiep Khong; Manisha Singh; Meenu Sharma; Faisal Faak; Derek Moore; Zhimin Dai; Scott M Anthony; Kimberly S Schluns; Padmanee Sharma; Victor H Engelhard; Willem W Overwijk
Journal:  J Clin Invest       Date:  2018-02-26       Impact factor: 14.808

4.  Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy.

Authors:  Jinyang Li; Katelyn T Byrne; Fangxue Yan; Taiji Yamazoe; Zeyu Chen; Timour Baslan; Lee P Richman; Jeffrey H Lin; Yu H Sun; Andrew J Rech; David Balli; Ceire A Hay; Yogev Sela; Allyson J Merrell; Shannon M Liudahl; Naomi Gordon; Robert J Norgard; Salina Yuan; Sixiang Yu; Timothy Chao; Shuai Ye; T S Karin Eisinger-Mathason; Robert B Faryabi; John W Tobias; Scott W Lowe; Lisa M Coussens; E John Wherry; Robert H Vonderheide; Ben Z Stanger
Journal:  Immunity       Date:  2018-06-26       Impact factor: 43.474

Review 5.  T-cell exhaustion in the tumor microenvironment.

Authors:  Y Jiang; Y Li; B Zhu
Journal:  Cell Death Dis       Date:  2015-06-18       Impact factor: 8.469

Review 6.  Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?

Authors:  Jean-Charles Cancel; Karine Crozat; Marc Dalod; Raphaël Mattiuz
Journal:  Front Immunol       Date:  2019-02-12       Impact factor: 7.561

7.  A new paradigm for tumor immune escape: β-catenin-driven immune exclusion.

Authors:  Stefani Spranger; Thomas F Gajewski
Journal:  J Immunother Cancer       Date:  2015-09-15       Impact factor: 13.751

8.  Tumor-Derived CXCL1 Promotes Lung Cancer Growth via Recruitment of Tumor-Associated Neutrophils.

Authors:  Ming Yuan; Ha Zhu; Junfang Xu; Yuanyuan Zheng; Xuetao Cao; Qiuyan Liu
Journal:  J Immunol Res       Date:  2016-06-29       Impact factor: 4.818

Review 9.  Abscopal Effect of Radiotherapy in the Immunotherapy Era: Systematic Review of Reported Cases.

Authors:  Nergiz Dagoglu; Sule Karaman; Hale B Caglar; Ethem N Oral
Journal:  Cureus       Date:  2019-02-20

10.  Tumor Size Matters-Understanding Concomitant Tumor Immunity in the Context of Hypofractionated Radiotherapy with Immunotherapy.

Authors:  Jean Philippe Nesseler; Mi-Heon Lee; Christine Nguyen; Anusha Kalbasi; James W Sayre; Tahmineh Romero; Philippe Nickers; William H McBride; Dörthe Schaue
Journal:  Cancers (Basel)       Date:  2020-03-18       Impact factor: 6.639

View more
  6 in total

Review 1.  Defining Immunogenic and Radioimmunogenic Tumors.

Authors:  Terry R Medler; Tiffany C Blair; Marka R Crittenden; Michael J Gough
Journal:  Front Oncol       Date:  2021-03-19       Impact factor: 6.244

2.  Radon Improves Clinical Response in an Animal Model of Rheumatoid Arthritis Accompanied by Increased Numbers of Peripheral Blood B Cells and Interleukin-5 Concentration.

Authors:  Lisa Deloch; Stephanie Hehlgans; Michael Rückert; Andreas Maier; Annika Hinrichs; Ann-Sophie Flohr; Denise Eckert; Thomas Weissmann; Michaela Seeling; Falk Nimmerjahn; Rainer Fietkau; Franz Rödel; Claudia Fournier; Benjamin Frey; Udo S Gaipl
Journal:  Cells       Date:  2022-02-16       Impact factor: 6.600

3.  TGFβ receptor inhibition unleashes interferon-β production by tumor-associated macrophages and enhances radiotherapy efficacy.

Authors:  Pauline Hamon; Marine Gerbé De Thoré; Marion Classe; Nicolas Signolle; Winchygn Liu; Olivia Bawa; Lydia Meziani; Céline Clémenson; Fabien Milliat; Eric Deutsch; Michele Mondini
Journal:  J Immunother Cancer       Date:  2022-03       Impact factor: 12.469

Review 4.  Combined treatment of non-small cell lung cancer using radiotherapy and immunotherapy: challenges and updates.

Authors:  Shijie Shang; Jie Liu; Vivek Verma; Meng Wu; James Welsh; Jinming Yu; Dawei Chen
Journal:  Cancer Commun (Lond)       Date:  2021-10-17

Review 5.  Current Prospects for Treatment of Solid Tumors via Photodynamic, Photothermal, or Ionizing Radiation Therapies Combined with Immune Checkpoint Inhibition (A Review).

Authors:  Sanjay Anand; Timothy A Chan; Tayyaba Hasan; Edward V Maytin
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-10

6.  Low-Dose Radiotherapy Leads to a Systemic Anti-Inflammatory Shift in the Pre-Clinical K/BxN Serum Transfer Model and Reduces Osteoarthritic Pain in Patients.

Authors:  Thomas Weissmann; Michael Rückert; Jian-Guo Zhou; Michaela Seeling; Sebastian Lettmaier; Anna-Jasmina Donaubauer; Falk Nimmerjahn; Oliver J Ott; Markus Hecht; Florian Putz; Rainer Fietkau; Benjamin Frey; Udo S Gaipl; Lisa Deloch
Journal:  Front Immunol       Date:  2022-01-03       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.